News Bluebird bio details plans to file three blockbusters Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
News Celgene in talks to buy CAR-T partner Juno Celgene is understood to be in talks to buy CAR-T specialists Juno Therapeutics, in a deal which could be worth around $7 billion.
News Cellectis gets FDA go-ahead to restart fatal CAR-T trial Regulator agrees to restart phase 1 trial of UCART 123
News Kite in CAR-T pole position as rolling submission begins Kite to start filing data for KTE-C19 with US regulator.
News Despite study bust, Vistagen still hopes to file anxiety dru... Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
